Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Colorectal Cancer, Colon Cancer, Rectal Cancer, Solid Tumor
Interventions: CB-839, Capecitabine; Drug
Lead sponsor: David Bajor, MD; Other
Eligibility: 19 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Squamous Cell Carcinoma of Skin, Cutaneous Squamous Cell Carcinoma (CSCC)
Interventions: Blood Specimen Collection, Tumor Tissue Collection, Medical Record Review; Procedure · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions: Milademetan, AZA; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 5
States / cities: Duarte, California • San Francisco, California • Fairway, Kansas + 2 more

Conditions: Covid19, SARS-CoV Infection, SARS-CoV-2, Corona Virus Infection
Interventions: Specimen Collection, Surveys; Diagnostic Test
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Heart Failure
Interventions: Nebulized Sodium Nitrite, Placebo; Drug
Lead sponsor: Adrian Hernandez; Other
Eligibility: 40 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 20
States / cities: Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 11 more

Conditions: Central Precocious Puberty (CPP)
Interventions: Leuprolide Acetate (LA); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 17
States / cities: Long Beach, California • San Diego, California • Aurora, Colorado + 14 more

Conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Interventions: Atumelnant, Placebo; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more

Conditions: Sinus Node Dysfunction
Interventions: Treadmill/Bicycle exercise testing; Diagnostic Test
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Stroke, Ischemic
Interventions: wearable wristband model, Samsung Galaxy Watch 6, Standard of care extended ECG monitoring; Device · Other
Lead sponsor: Emory University; Other
Eligibility: 55 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy Volunteer
Interventions: Litifilimab, AI, OBI, PFS; Drug · Device
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 404 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Las Vegas, Nevada • Austin, Texas

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)
Interventions: INBRX-106, Pembrolizumab; Drug
Lead sponsor: Inhibrx Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 26
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 22 more

Conditions: Advanced Solid Tumor, Ovarian Cancer
Interventions: Neratinib 160 mg, Neratinib 200 mg, Neratinib 240 mg, Niraparib 100 mg, Niraparib 200 mg, Niraparib 300 mg, Niraparib at RP2D, Neratinib at RP2D; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Neoplasms
Interventions: ADH300004; Drug
Lead sponsor: Adherex Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Post-Operative Pain, Lumbar Laminectomy
Interventions: Bupivacaine HCI without epinephrine, HTX-011, Luer Lock Applicator; Drug · Device
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 12
States / cities: Phoenix, Arizona • Pasadena, California • Wichita, Kansas + 9 more

Conditions: Hypertension, Renal
Interventions: MLS-101 (Part I), Placebo (Part I), Placebo (Part II), MLS-101 (Part II); Drug · Other
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 44
States / cities: Lincoln, California • Torrance, California • Tustin, California + 38 more

Conditions: Joint Replacement, Arthropathy
Interventions: Patient-Specific Orthopedic Implant; Device
Lead sponsor: Restor3D; Industry
Eligibility: 18 Years and older
Enrollment: 2,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Leukemia
Interventions: Brentuximab Vedotin, 5-Azacytidine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Immunoglobulin A (IgA) Nephropathy
Interventions: PS-002; Genetic
Lead sponsor: Purespring Therapeutics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Miami, Florida • Baltimore, Maryland

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Interferon gamma-1b, Donor Leukocyte Infusion (DLI); Drug · Biological
Lead sponsor: Sawa Ito, MD; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: St Louis, Missouri • Pittsburgh, Pennsylvania • Seattle, Washington

Conditions: Epilepsy
Interventions: radiosurgery, temporal lobectomy; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 13
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more

Conditions: Healthy Participants
Interventions: Midazolam, GDC-0853, Midazolam and GDC-0853, Rosuvastatin, Rosuvastatin and GDC-0853, Simvastatin, Simvastatin and GDC-0853, Itraconazole, GDC-0853 and itraconazole; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 3
States / cities: Daytona Beach, Florida • Evansville, Indiana • Madison, Wisconsin

Conditions: Small Cell Lung Cancer
Interventions: ABBV-706, Topotecan, Lurbinectedin, Amrubicin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 37
States / cities: Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 32 more

Conditions: Functional Independence
Interventions: Behavioral Activation for Independence in Older Veterans (ACTIVaTE), Usual care; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 65 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Bedford, Massachusetts

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Phase I and Phase II: LAE001/prednisone + afuresertib; Drug
Lead sponsor: Laekna Limited; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 12
States / cities: Tucson, Arizona • Encinitas, California • Norwich, Connecticut + 9 more

Search by objective public record fields.

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Epidemiologic Assessment of SARS-CoV-2 (COVID-19) Prevalence in Minnesota

Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF

A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

Effectiveness of Closed Loop Stimulation (CLS) With His Bundle Lead Placement

DELTA (Detecting and Predicting Atrial Fibrillation in Post-Stroke Patients)

A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways

Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)

Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer

A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors

HTX-011 in Spinal Surgery

Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension

The restor3d Outcomes Registry

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

PS-002 for the Treatment of IgA Nephropathy in Adults

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

Radiosurgery or Open Surgery for Epilepsy Trial

A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and Simvastatin

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

Behavioral Activation for Independence in Older Veterans

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC